Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

This study is testing whether high-dose intravenous vitamin C (ascorbic acid) given alongside standard chemotherapy — and sometimes immunotherapy — can improve outcomes for people with advanced non-small cell lung cancer. Laboratory studies suggest high-dose vitamin C may enhance the effects of chemotherapy and reduce side effects. **You may be eligible if...** - You are 18 or older - You have been diagnosed with stage IIIB or stage IV non-small cell lung cancer (advanced or widespread disease) - You are eligible for and scheduled to begin standard first-line platinum-based chemotherapy - You are in reasonably good overall health **You may NOT be eligible if...** - You have previously received chemotherapy for lung cancer - You have a genetic condition called G6PD deficiency (which makes high-dose vitamin C unsafe) - You have kidney stones or significant kidney problems - You are pregnant or breastfeeding - Your performance status is too poor to tolerate treatment Talk to your doctor to see if this trial is right for you.